OMNIAB, INC. Net Change in Cash
OMNIAB, INC. (OABI) reported Net Change in Cash of -$1.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- OMNIAB, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $3.52M.
- OMNIAB, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$16.71M, a 718.28% decline year-over-year.
- OMNIAB, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $2.70M.
- OMNIAB, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$10.53M.
- OMNIAB, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$2.07M, a 118.45% decline from fiscal 2024.
- OMNIAB, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $11.24M.
- OMNIAB, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$16.92M, a 150.00% decline from fiscal 2022.
- OMNIAB, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $33.84M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.19M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $3.52M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$2.07M 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $939.00K 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | -$9.32M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$16.71M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $11.24M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | $10.88M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $4.44M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $2.70M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$16.92M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | -$12.03M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$12.29M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$10.53M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $33.84M 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |